Literature DB >> 2002231

Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections.

M Kremer1, R Zuckerman, Z Avraham, R Raz.   

Abstract

Thirty-six patients who had suffered two or more episodes of erysipelas or cellulitis during the previous year were randomly divided into two equal groups; one group received erythromycin base 250 mg b.i.d. for 18 months, while the other group received no prophylaxis for a similar period. No patients in the treated group developed infection during the 18 months' follow-up but eight of the control group (50%) relapsed and required antibiotic treatment. Prolonged antimicrobial prophylaxis is effective and safe in preventing recurrent episodes of soft-tissue infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2002231     DOI: 10.1016/0163-4453(91)90898-3

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  15 in total

1.  Risk factors for erysipelas of the leg (cellulitis): case-control study.

Authors:  A Dupuy; H Benchikhi; J C Roujeau; P Bernard; L Vaillant; O Chosidow; B Sassolas; J C Guillaume; J J Grob; S Bastuji-Garin
Journal:  BMJ       Date:  1999-06-12

2.  Recurrent cellulitis: risk factors, etiology, pathogenesis and treatment.

Authors:  Maciej Piotr Chlebicki; Choon Chiat Oh
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

3.  A 60-year-old woman with recurrent cellulitis.

Authors:  Rohit Vijh; Rupal Shah; Nisha Andany
Journal:  CMAJ       Date:  2019-03-04       Impact factor: 8.262

4.  Low-dose penicillin for recurrent cellulitis?

Authors:  Liz Nguyen; Kate Rowland
Journal:  J Fam Pract       Date:  2014-01       Impact factor: 0.493

5.  Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis.

Authors:  J Carratalà; B Rosón; N Fernández-Sabé; E Shaw; O del Rio; A Rivera; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

6.  A framework for analysis of research risks and benefits to participants in standard of care pragmatic clinical trials.

Authors:  Stephanie C Chen; Scott Yh Kim
Journal:  Clin Trials       Date:  2016-06-30       Impact factor: 2.486

Review 7.  Cellulitis and erysipelas.

Authors:  Andrew D Morris
Journal:  BMJ Clin Evid       Date:  2008-01-02

8.  Antibiotic prophylaxis in recurrent erysipelas.

Authors:  A C Sjöblom; B Eriksson; C Jorup-Rönström; K Karkkonen; M Lindqvist
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

9.  Cellulitis and erysipelas: prevention.

Authors:  Choon Chiat Oh
Journal:  BMJ Clin Evid       Date:  2015-11-18

10.  Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial.

Authors:  Kim Thomas; Angela Crook; Katharine Foster; James Mason; Joanne Chalmers; John Bourke; Adam Ferguson; Nick Level; Andrew Nunn; Hywel Williams
Journal:  Br J Dermatol       Date:  2011-12-06       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.